Open access
Sep 2026
Efficacy of HER2-targeted therapy in early breast cancer 2008–2020 in Sweden in the real-world setting
Large-scale real-world evidence on outcomes in HER2-positive (HER2 +) early breast cancer (EBC) remains limited. We investigated overall survival (OS) and its prognostic factors in patients with HER2+ EBC. We here analyzed data from 4,638 patients with HER2 + EBC diagnosed between 2008 and 2020, retrieved from the Swed...
A. Haidar, Malin Rimskog, Jenny Nyqvist-Streng et al.
· Scientific Reports · 0 citations